142731-84-8

Basic information

• Product Name: (3-(BENZYLOXYMETHYL)OXETAN-3-YL)METHANOL
• Synonyms: (3-(BENZYLOXYMETHYL)OXETAN-3-YL)METHANOL
• CAS NO: 142731-84-8
• Molecular Formula: C₁₂H₁₆O₃
• Molecular Weight: 208.255
• Mol File: 142731-84-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3-(BENZYLOXYMETHYL)OXETAN-3-YL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (3-(BENZYLOXYMETHYL)OXETAN-3-YL)METHANOL(142731-84-8)
• EPA Substance Registry System: (3-(BENZYLOXYMETHYL)OXETAN-3-YL)METHANOL(142731-84-8)

Safety Data

• Hazardous Substances Data: 142731-84-8(Hazardous Substances Data)

Usage

Description

(3-(Benzyloxymethyl)oxetan-3-yl)methanol is a white, crystalline solid with the molecular formula C12H14O3. It is a derivative of oxetane, a heterocyclic molecule containing a three-membered ring with an oxygen atom. The benzyloxymethyl group attached to the oxetane ring provides chemical reactivity and stability, making it useful in the synthesis of complex organic molecules.

Uses

Used in Pharmaceutical Industry:
(3-(Benzyloxymethyl)oxetan-3-yl)methanol is used as a building block for the synthesis of various compounds in the pharmaceutical industry. Its unique structure and properties make it a valuable tool for organic chemists in the development of new materials and compounds.
Used in Agrochemical Industry:
(3-(Benzyloxymethyl)oxetan-3-yl)methanol is also used as a building block for the synthesis of various compounds in the agrochemical industry. Its chemical reactivity and stability contribute to the development of new agrochemical products.

Upstream product

• 2754-18-9 3,3-bis(hydroxymethyl)oxetane 
• 100-39-0 benzyl bromide 
• 500358-88-3 2-(benzyloxymethyl)-2-(toluene-4-sulfonyloxymethyl)-1,3-propanediol 
• 130147-42-1 2-<(benzyloxy)methyl>-2-(hydroxymethyl)-1,3-propanediol 
• 115-77-5 Pentaerythritol 

Downstream Products

• 142732-09-0 1,11-di(benzyloxy)-2,2;6,6;10,10-tris(2-oxapropane-1,3-diyl)-4,8-dioxaundecane 
• 142731-88-2 1,11-di(benzyloxy)-6,6-dimethyl-2,2;10,10-bis(2-oxapropane-1,3-diyl)-4,8-dioxaundecane 
• 142731-91-7 3-benzyloxymethyl-3-allyloxymethyloxetane 
• 142731-86-0 3-benzyloxymethyl-3-tosyloxymethyloxetane 
• 142731-95-1 11-tosyloxy-2,2;10,10-bis(2-oxapropane-1,3-diyl)-4,8-dioxa-1-undecanol 
• 142731-87-1 1,11-di(benzyloxy)-2,2;10,10-bis(2-oxapropane-1,3-diyl)-4,8-dioxaundecane 
• 142731-96-2 6,6-dimethyl-11-tosyloxy-2,2;10,10-bis(2-oxapropane-1,3-diyl)-4,8-dioxa-1-undecanol 
• 142731-97-3 6-methoxymethyl-6-methyl-11-tosyloxy-2,2;10,10-bis(2-oxapropane-1,3-diyl)-4,8-dioxa-1-undecanol 
• 142731-89-3 1,11-di(benzyloxy)-6-methoxymethyl-6-methyl-2,2;10,10-bis(2-oxapropane-1,3-diyl)-4,8-dioxaundecane 
• 142731-98-4 C₂₇H₃₆O₁₀S₂ 
• 142731-99-5 C₂₉H₄₀O₁₀S₂ 

Relevant articles and documents

ISOQUINOLINONE COMPOUND AND USE THEREOF IN PREPARATION OF ANTIVIRAL DRUGS

Disclosed is an isoquinolinone compound as shown in Formula (I) or a stereoisomer, pharmaceutically acceptable salt, solvate or crystal thereof, and a preparation method thereof, and use thereof in the preparation of drugs for treating or preventing viral infectious diseases caused by the hepatitis B virus (HBV) and other viruses, in particular, use thereof in drugs as HBV surface antigen inhibitors and HBV DNA production inhibitors. The compound has a significant activity in inhibiting hepatitis B surface antigen and hepatitis B DNA, and is possible to significantly improve the probability of curing hepatitis B by administration in combination with nucleoside drugs or other drugs in the future, and has good clinical application prospects.

ARYL GLYCOSIDE COMPOUND, PREPARATION METHOD AND USE THEREOF

Disclosed are an aryl glycoside compound as represented by formula I or formular I′, a pharmaceutically acceptable salt thereof, optical isomer thereof or a prodrug thereof. The present invention relates to a method of preparing said aryl glycoside compound and the use thereof The aryl glycoside compound of the present invention has an excellent ability on inhibit SGLT activity, especially SGLT2 activity, and is diabetes-fighting medicine with great potential.

Novel lipid A mimetics derived from pentaerythritol: Synthesis and their potent agonistic activity

A pentaerythritol unit is substituted for glucosamine as its functional mimic at the reducing end of lipid A disaccharide. Two such pentaerythritol derived lipid A mimetics 3 and 4, carrying three identical fatty acyl moieties, have been designed and synt